<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260225068949N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-04-27</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison the Effect of Mindfulness-Based Cognitive Therapy and Progressive Muscle Relaxation on Inflammatory Bowel Disease Patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the Effect of Mindfulness-Based Cognitive Therapy and Progressive Muscle Relaxation on Symptoms, Fatigue, and Visceral Hypersensitivity in Inflammatory Bowel Disease Patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/89604</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This Study is a Block Randomization Clinical Trial with Two Intervention Groups and is Conducted in an Unblinded Manner. The Sample of This Design Includes 72 Patients with Inflammatory Bowel Disease.
After Reviewing and Evaluating the Files of the Affected Patients and also Evaluating the Patients Diagnosed with Inflammatory Bowel Disease by a Specialist Physician and after Their Agreement to Participate in this Design and also Evaluating the Entry Conditions; with the Help of a Statistical Consultant and Based on Statistical Software; Blocks of 9 Sizes are Created, Which will Ultimately Create 8 Blocks of 9 and 36 Patients will be Placed in Each Group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Inflammatory Bowel Disease (IBD). Condition 2: Inflammatory Bowel Disease (IBD).</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1: This Group of Patients with Inflammatory Bowel Disease (IBD) Received Mindfulness-Based Cognitive Therapy in a Group Setting Over 8 Two-Hour Sessions. Session 1: Introduction and Explanation of the Sessions’ General Content and Awareness and Automatic Guidance   Session 2: Living in Our Minds (Paying Attention to Breathing)    Session 3: Gathering the Wandering Mind    Session 4: Recognizing Aversion    Session 5: Allowing/Coping    Session 6: Thoughts are not Reality.     Session 7: How can I Best Take Care of Myself?         Session 8: Retaining and Expanding New Learning. Also, at the End of Each Session, There are a Series of Exercises That are Given to The Patient to Study and Do for The Next Session. Intervention 2: Intervention group 2: This Group of Patients with Inflammatory Bowel Disease (IBD) Received Progressive Muscle Relaxation in 8 Two-Hour Sessions as a Group. Session 1: Justification of The Treatment Logic and Breathing Relaxation    Session 2: Relaxation of 16 Muscle Groups Session 3: Relaxation of 7 Muscle Groups    Session 4: Relaxation of 4 Muscle Groups    Session 5: Relaxation Through Reminders    Session 6: Relaxation Through Reminders with Counting    Session 7: Relaxation Through Counting    Session 8: Final Feedback on The Intervention Process and Post-Test                                                                                    At The Beginning of Each Session, Questions from Individuals about the Previous Session are Answered, and at The End of The Sessions, Guidance is Provided on How to Complete Assignments.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All Data about Participants Can be Shared After Individuals are De-identified.

When:
Access Period Starts 6 Months After Results are Published

To whom:
Researchers Working in Academic and Scientific Institutions

Conditions:
The Data is Provided Solely for The Purpose of Better Understanding The Research Methodology. Therefore, Analysis of The Data is not Permitted.

Where to obtain:
Sara Ahmadi: Sa.Ahmadi.9731@gmail.com   Phone: 09367581699              Dr. Fatemeh Zargar:  fatemehzargar@gmail.com

How to obtain:
First, Send an Email to Ms. Ahmadi. If You do not Receive a Response from The University Email, Send a Message to Her Personal Email. Otherwise, Send a Message to Dr. Fatemeh Zargar's Email. We Will Try to Respond Within a Week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sara Ahmadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan University of Medical Sciences, Hezar Jerib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81458-33117</zip>
        <telephone>+98 31 3792 8101</telephone>
        <email>Sa.Ahmadi.9731@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Fatemeh Zargar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan University of Medical Sciences, Hezar Jerib Street</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3792 8101</telephone>
        <email>fatemehzargar@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Possessing Minimum Age of 18 Years and a Maximum Age of 65 Years
Definitive Diagnosis of Crohn's Disease or Ulcerative Colitis by a Specialist physician
Ability to Participate in 8 Treatment Sessions
Having at Least a High School Diploma
Completing the Informed Consent Form
Ability to Perform Light Exercise Like Raising Arms Above Head or Bending Knees</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having Major Psychiatric Disorder Such as Psychotic Disorders, Substance Use Disorders, Mood disorders
Participation in Other Psychosocial Trials</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K50</hc_code>
      <hc_code>K51</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Crohn's disease [regional enteritis]</hc_keyword>
      <hc_keyword>Ulcerative colitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: This Group of Patients with Inflammatory Bowel Disease (IBD) Received Mindfulness-Based Cognitive Therapy in a Group Setting Over 8 Two-Hour Sessions. Session 1: Introduction and Explanation of the Sessions’ General Content and Awareness and Automatic Guidance   Session 2: Living in Our Minds (Paying Attention to Breathing)    Session 3: Gathering the Wandering Mind    Session 4: Recognizing Aversion    Session 5: Allowing/Coping    Session 6: Thoughts are not Reality.     Session 7: How can I Best Take Care of Myself?         Session 8: Retaining and Expanding New Learning. Also, at the End of Each Session, There are a Series of Exercises That are Given to The Patient to Study and Do for The Next Session.</i_keyword>
      <i_keyword>Intervention group 2: This Group of Patients with Inflammatory Bowel Disease (IBD) Received Progressive Muscle Relaxation in 8 Two-Hour Sessions as a Group. Session 1: Justification of The Treatment Logic and Breathing Relaxation    Session 2: Relaxation of 16 Muscle Groups Session 3: Relaxation of 7 Muscle Groups    Session 4: Relaxation of 4 Muscle Groups    Session 5: Relaxation Through Reminders    Session 6: Relaxation Through Reminders with Counting    Session 7: Relaxation Through Counting    Session 8: Final Feedback on The Intervention Process and Post-Test                                                                                    At The Beginning of Each Session, Questions from Individuals about the Previous Session are Answered, and at The End of The Sessions, Guidance is Provided on How to Complete Assignments.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Symptoms. Timepoint: Before the Intervention, After the Intervention, 3 Months After the Intervention. Method of measurement: Inflammatory Bowel Disease Questionnaire-Short Form.</prim_outcome>
      <prim_outcome>Fatigue. Timepoint: Before the Intervention, After the Intervention, 3 Months After the Intervention. Method of measurement: Multidimensional Fatigue Inventory.</prim_outcome>
      <prim_outcome>Visceral Hypersensitivity. Timepoint: Before the Intervention, After the Intervention, 3 Months After the Intervention. Method of measurement: Visceral Sensitivity Index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-02-08</approval_date>
        <contact_name>Research Ethics Committees of School of Medicine - Isfahan University of Medical Sciences</contact_name>
        <contact_address>Building No. 3, Isfahan University of Medical Sciences, Hezar Jerib Street Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
